People in the News
Biotech company Encodia hired Nigel Beard as its chief technology officer (CTO). Bear recently served as CTO and senior vice president of operations at Mission Bio, where he was involved in launching and scaling up that company's multiomic single cell analysis Tapestri platform.
Prior to Mission, Beard worked as CTO and chief operating officer at Feetz, head of R&D at Life Technologies' Human Identification Business, and as senior program manager at Applied Biosystems. Additionally, Beard serves as a board member at Savran Technologies.
Enzo Biochem has appointed Hamid Erfanian as its CEO. Elazar Rabbani, the firm's outgoing CEO, remains chairperson of the board of directors and will assume the role of chief scientific officer.
Erfanian was most recently chief commercial officer of PerkinElmer's Euroimmun. From June 2014 to Aug. 2021, he was CEO of Euroimmun's US subsidiary. Prior to Euroimmun, Erfanian held executive and senior positions at several diagnostics companies including Diagnostica Stago, Beckman Coulter, and Abbott Laboratories. Earlier in his career, he worked at Quest Diagnostics and Laboratory Corporation of America.
Geneoscopy has appointed Haytham Gareer as chief medical officer. Gareer will assist in the company's efforts to launch its non-invasive RNA-FIT colorectal cancer screening test and in expanding Geneoscopy's gastrointestinal diagnostics portfolio.
Gareer previously served as vice president and global head of medical and clinical affairs for Olympus Corporation, where he led clinical research efforts and collaborations with medical advisors in support of commercialization and technology development across the company's medical products portfolio. Prior to that, Gareer practised as as surgeon, with internation experience in Egypt, Italy, and Japan.
Illumina has appointed Bob Ragusa as CEO of its subsidiary Grail. He succeeds Hans Bishop, who will serve as advisor to the CEO through the end of 2021 and then step down.
Ragusa is Illumina's chief operations officer, a role in which he helped scale the business globally. He was responsible for the company's clinical lab services, supply chain, quality, life cycle management, information technology, global facilities, and real estate teams.
Prior to Illumina, he was executive VP of engineering and global operations at Accuray, a radiation oncology company, and senior VP of global operations at Applied Biosystems.
Ragusa holds a master's degree in biomedical and electrical engineering from Carnegie Mellon University and an MBA from the University of Connecticut.
Bishop joined Grail's board of directors in 2018 before becoming CEO. He founded Juno Therapeutics in 2013 and was the firm's president and CEO until it was acquired by Celgene. He serves on the boards of Celgene and Agilent Technologies.
Andreas Tsukada has joined Caris Life Sciences as senior vice president, president of Japanese operations and head of international. In his new role, Tsukada will oversee operations, market development, regulatory strategy, biopharma partnerships, and strategic initiatives in the region, as well as support Caris' molecular profiling collaboration with the National Cancer Center Japan for the MONSTAR-SCREEN-2 of SCRUM-Japan, the largest cancer genomic screening consortium in the country.
Before joining Caris, Tsukada was general manager and representative director for Japan at Guardant Health. He has over 20 years experience in oncology and diagnostics across the US, Europe, and Asia-Pacific, including working with Thermo Fisher Scientific, where he directed clinical NGS partnerships. Prior to that, Tsukada worked for Merck Biopharma in Japan leading the oncology business unit.
Personalis has appointed Robert Bruce to the newly created position of vice president of reimbursement. Bruce previously worked at Clinical Genomics, where he served as VP of reimbursement and interim CFO. Prior to Clinical Genomics he provided reimbursement and financial consulting services to a range of private and public companies, after serving in senior management roles with Enterix and Binax. He holds a BA in East Asian studies from Princeton University and an MBA from the School of Management at Yale University.
IDbyDNA has made several appointments to its scientific advisory board. Joining the board are Adrian Egli, head of clinical bacteriology and mycology at University Hospital Basel, Switzerland; Tamara Feldblyum, former branch chief in the Division of Microbiology Devices at the US Food and Drug Administration's Center for Devices and Radiological Health Office of In Vitro Diagnostics and Radiological Health; Karl Voelkerding, an expert in genomics and a member of the College of American Pathologists and the Association for Molecular Pathology; Christopher Woods, executive director of the Hubert-Yeargan Center for Global Health and professor of medicine and pathology at Duke University; and Stephen Young, director of research and clinical trials at TriCore Reference Laboratory.
Metabolomics and precision medicine company Metabolon has appointed Rangaprasad (Ranga) Sarangarajan as its chief scientific officer (CSO).
Sarangarajan previously served as CSO and senior vice president of clinical and translational sciences at BERG, where he led the development of a multi-omic, biology-based platform for identifying disease-specific targets and novel therapeutics, and developing diagnostics. He also helped establish that company's pipeline of assets in various diseases and indications, and led several programs through early IND, including enabling a first-in-human Phase I and proof-concept Phase II clinical program.
Sarangarajan obtained a PhD in pharmaceutical sciences from the University of Cincinnati and is part of over 40 pending or approved patents.
René Salazar has joined the Broad Institute as chief equity officer, a newly created position, and has become a member of the institute's executive leadership team. Previously, he was assistant dean for diversity and a professor of internal medicine and medical education at the University of Texas at Austin Dell Medical School. Salazar holds a medical degree from the University of Texas Health San Antonio School of Medicine.
Foundation Medicine has appointed Dymeka Harrison as chief commercial officer, where she will develop and execute global clinical commercial strategy and strengthen customer relationships, as well as establish new partnerships. She most recently served as VP of global strategic marketing at Abbott, overseeing global marketing efforts for the firm's rapid diagnostics division. Harrison also worked at Qiagen as VP of sales for its QuantiFeron and AmniSure businesses and was a national sales manager in the clinical division at BioMérieux. She has also served as a sales director at Thermo Fisher Scientific.